Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Keppra Clear all
Recruiting Phase 2 Interventional

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717
View directory record Official record
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions

NCT01132352
View directory record Official record
Conditions
Healthy
Interventions
Levetiracetam
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2010 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Levetiracetam in the Management of Bipolar Depression

NCT00566150
View directory record Official record
Conditions
Bipolar Depression
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

NCT02348216
View directory record Official record
Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
Interventions
Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 5, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

NCT00068770
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
radiation therapy, Celecoxib
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacological Modulation of Hippocampal Activity in Psychosis 2

NCT04559529
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam (LEV) 500 mg, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

NCT00961441
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 5, 2026, 6:42 AM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia

NCT02199509
View directory record Official record
Conditions
Oromandibular Dystonia, Cranial Dystonia
Interventions
Levetiracetam
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 5, 2026, 6:42 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

NCT04833907
View directory record Official record
Conditions
Canavan Disease
Interventions
rAAV-Olig001-ASPA, Levetiracetam, Prednisone
Drug
Lead sponsor
Myrtelle Inc.
Industry
Eligibility
3 Months to 60 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Results available

Characterization of Epilepsy Patients BEEP 2b

NCT02707965
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine (brand name vs generic drugs), Divalproex Sodium (brand name vs generic drugs), Carbamazepine (brand name vs generic drugs), Lamotrigine (brand name vs generic drugs), levetiracetam (brand name vs generic drugs), Topiramate (brand name vs generic drugs), Zonisamide (brand name vs generic drugs), Phenytoin sodium (brand name vs generic drugs)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 76 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 5, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacologic Modulation of Hippocampal Activity in Psychosis

NCT04277936
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam 500 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

NCT00141115
View directory record Official record
Conditions
Alcoholism, Generalized Anxiety Disorder, Panic Disorder, Social Phobia, Anxiety Disorders
Interventions
levetiracetam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356
View directory record Official record
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Established Status Epilepticus Treatment Trial

NCT01960075
View directory record Official record
Conditions
Benzodiazepine Refractory Status Epilepticus
Interventions
Fosphenytoin, Levetiracetam, Valproic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
2 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
65
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 5, 2026, 6:42 AM EDT
Completed No phase listed Observational

Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

NCT03071913
View directory record Official record
Conditions
Central Nervous System Neoplasm, Localized Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 5, 2026, 6:42 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926
View directory record Official record
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Not applicable Interventional

A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy

NCT00361010
View directory record Official record
Conditions
Epilepsy, Childhood Absence Epilepsy, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
4 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Sep 5, 2026, 6:42 AM EDT
Recruiting Phase 3 Interventional

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173
View directory record Official record
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
52
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00247364
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Sleep Health Centers
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2005 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 3 Interventional

Levetiracetam Treatment of Tardive Dyskinesia

NCT00291213
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
levetiracetam, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

NCT00152516
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
levetiracetam (LEV)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 16 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 5, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 5, 2026, 6:42 AM EDT